They also highlight that IDH mutation is a target for small molecule inhibition and immune therapy in diffuse astrocytomas and oligodendrogliomas, while the BRAF pathway is targetable in circumscribed gliomas [10]. This evidence concerns the gene IDH2 and oligodendroglioma.